Herve Allain, M.D., Daniele Bentue-Ferrer, Ph

HERVE ALLAIN, M.D., DANIELE BENTUE-FERRER, PH.D., SERGE BELLIARD, M.D. and CHRISTIAN DEROUESNE, M.D. [Pg.1]

Primary progressive aphasia and other focal atrophies 10 [Pg.1]

Pre- and post-excitatory amino acid markers in Alzheimer s disease -Amyloid neurotoxicity Neurotrophic factors Neurofibrillary tangles [Pg.2]

EARLY PHASES OF CLINICAL DEVELOPMENT OF DRUGS FOR ALZHEIMER S DISEASE Requirements for initial clinical steps The decision to undertake trials Theoretical basis of mechanism of action Symptomatic action versus aetlopathology Methodology [Pg.2]

An example the hippocampus in Alzheimer s disease The mechanistic aim of pharmacology Hippocampus-specific endpoints Choice of representative subjects Conclusion Perspectives [Pg.2]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...